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Abstract: The aims of this systematic review are (1) to compare the prevalence of xerostomia
and hyposalivation between patients taking antihypertensive drugs with a control group (CG),
(2) to compare salivary flow rate between patients treated with a CG, and (3) to identify which
antihypertensives produce xerostomia. This systematic review was carried out according to the
preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. To evaluate
methodological quality of the eligible studies Cochrane Collaboration tool for assessing the risk
of bias for clinical trials and the modified Newcastle–Ottawa scale case-control studies were used.
The databases were searched for studies up to November 19th 2019. The search strategy yielded
6201 results and 13 publications were finally included (five clinical trials and eight case-control
studies). The results of the included studies did not provide evidence to state that patients taking
antihypertensives suffer more xerostomia or hyposalivation than patients not taking them. With
regard to salivary flow, only two clinical studies showed a significant decrease in salivary flow
and even one showed a significant increase after treatment. The case–control studies showed great
variability in salivary flow, but in this case most studies showed how salivary flow is lower in patients
medicated with antihypertensive drugs. The great variability of antihypertensive drugs included,
the types of studies and the outcomes collected made it impossible to study which antihypertensive
drug produces more salivary alterations. The quality assessment showed how each of the studies
was of low methodological quality. Therefore, future studies about this topic are necessary to confirm
whether antihypertensive drugs produce salivary alterations.
Keywords: antihypertensives; hypertension; xerostomia; hyposalivation; salivary flow
1. Introduction
Hypertension (HT) is a chronic medical condition in which blood pressure (BP) in the arteries
is elevated. HT is currently defined as values in systolic BP > 140 mmHg and/or diastolic
BP > 90 mmHg [1–3]. The prevalence of HT has increased substantially between 1990 and 2015 with
a corresponding increase in deaths associated with this condition. In 2015, the Non-Communicable
Diseases Risk Factor Collaboration (NCD RisC) estimated that 1.13 billion adults had HT [4].
Non-pharmacologic therapy with an appropriate lifestyle modification is recommended for all
patients with HT. In addition, antihypertensive medication is recommended in many cases, and should
be considered in others who have not achieved a goal BP despite non-pharmacologic therapy [5]. With
regard to the current Guidelines for HT Management, among the first line antihypertensive drugs are
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angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, calcium
channel blockers, and diuretics [3].
Saliva is one of the most essential fluids of the body [6,7] with a number of important functions
that are essential for maintaining oral health [8]. Xerostomia is a subjective complaint of dry mouth,
whereas hyposalivation is an objective decrease of salivary flow [9]. There are a number of physiological
situations that can alter salivary flow rate such as age, sex, body weight, number of teeth present in
mouth, or time of day. Xerostomia takes place when taking certain drugs, radiotherapy treatment for
head and neck cancer, chronic rheumatic diseases such as Sjögren’s syndrome, and other systemic
disorders such as diabetes mellitus [7]. More than one thousand drugs are reported to be associated
with xerostomia. Tricyclic antidepressants, muscarinic receptor antagonists, antipsychotics, opioids
and benzodiazepines, antihypertensives, and antihistamines are the main medications producing this
effect [10]. Among the antihypertensive drugs with a remarkable association with salivary alterations
are β-adrenergic blockers, diuretics, ACE inhibitors, and drug combinations [1].
Although the side effects of antihypertensives have been widely studied [11–13], their effects on
saliva have not been clarified. Therefore, the main objectives of this systematic review are: (1) to compare
the prevalence of xerostomia and hyposalivation between patients taking antihypertensive drugs with
a control group (CG), (2) to compare salivary flow rate between patients taking antihypertensive drugs
with a CG, and (3) to identify which antihypertensives produce more xerostomia.
2. Materials and Methods
The present systematic review was performed according to PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-analyses) guidelines [14].
2.1. Focused Question
According to PRISMA guidelines, three focused questions were constructed. The questions were
as follows: (1) Do patients taking antihypertensives have more xerostomia or hyposalivation than
patients not taking them? (2) Is salivary flow lower in patients taking antihypertensives than in patients
not taking them? (3) Do all antihypertensives reduce salivary flow in the same way?
2.2. Search Strategy
An exhaustive search of the literature was carried out, without prior limit restriction of the date
until November 19th, 2019. Four international biomedical literature databases were used to perform
the search: U.S National Library of Medicine (PubMed/MEDLINE), Web of Science (WOS), Cumulative
Index to Nursing and Allied Health Literature (CINAHL), and the Cochrane Library. These databases
were searched for studies using the following combination of terms: saliva, dry mouth, hyposalivation
OR salivary flow AND hypertension, antihypertensive drug, OR antihypertensives. These terms were
adjusted according to each database. An additional hand-search of the reference list of the reviewed
articles was performed to find potential eligible studies.
Two independent researchers (LR and FH) compared search results to ensure completeness. They
removed duplicated studies and screened full title and abstract of the remaining studies. A third
reviewer (RMLP) resolved any differences in the selection of the studies (Figure 1).
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 Figure 1. Flow chart.
2.3. Inclusion Criteria
Type of studies: studies had to be (1) original articles, (2) performed in humans, and (3) clinical
trials, longitudinal and cross-sectional studies.
Types of population: We included studies conducted on patients who started antihypertensive
therapy or were on antihypertensive therapy. Xerostomia, hyposalivation or salivary flow of these
patients had to be compared with a control (CG) or placebo group that did not receive antihypertensives,
did not suffer other diseases, and did not receive any other pharmacological treatments.
Outcomes: (1) Xerostomia or dry mouth was diagnosed based on different questions: Does your
mouth usually feel dry? Does your mouth feel dry when eating a meal? Do you have difficulty
swallowing dry food? Do you sip liquid to aid in swallowing dry food? Is the amount of saliva
in your mouth too little most of the time? Does your mouth feel dry right now? Do you wake up
at night to drink water? An affirmative response to one of these questions was enough to make a
diagnosis of xerostomia. (2) Moreover, xerostomia could be quantified using the visual analogue scale
(VAS) [15], xerostomia questions proposed by Fox et al. [16] or Xerostomia Inventory by Sreebney
and Fox modified by De la Luz et al. [17]. (3) Hyposalivation was considered when stimulated whole
saliva (SWS) was ≤0.7 mL/min or ≤0.5 mL/min. Unstimulated whole saliva (UWS) hyposalivation was
considered when it was ≤0.3 mL/min, ≤0.2 mL/min, ≤0.15 mL/min, or when the modified Schimer
test showed the strip color moved to 25 mm at 3 min. (4) Different types of salivary flow rates were
considered by different saliva sampling: UWS, SWS, stimulated parotid saliva (SPS), unstimulated
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submandibular/sublingual saliva (USS), and stimulated submandibular/sublingual saliva (SSS). The
amount of salivary flow could be expressed in mL/min or mg/min.
2.4. Exclusion Criteria
Studies were excluded when (1) hypertensive patients were not taking antihypertensives;
(2) studies were published in a language other than English and Spanish; (3) patients had concomitant
diseases or took other drugs; (4) if the results were not compared with a placebo or CG of patients not
taking antihypertensive drugs; and (5) if salivary flow rate was not shown in the numerical data but in
a graph or a box-plot without the exact data.
2.5. Data Collection and Extraction
LR and FH independently extracted the data. Any differences in this phase were resolved by
discussion with a third researcher (RMLP). The following data was collected: first author, publication
year, country of origin, study population, mean age and gender, saliva sampling method, xerostomia
and hyposalivation assessment, and type of antihypertensives. Outcomes extracted were the percentage
of patients suffering xerostomia and/or hyposalivation, degree of xerostomia and salivary flow rate of
patients taking antihypertensives, and placebo or CG.
Statistical signification was given if available. For the clinical trials that presented intermediate
assessments, we used the baseline scores and every follow-up score.
2.6. Risk of Bias in Individual Studies
Two independent researches (FH and LR) evaluated the methodological quality of each of the
eligible studies using the Cochrane Collaboration tool for assessing risk of bias for clinical trials [14]
and the modified Newcastle–Ottawa scale [18] for case-control studies.
The case-control studies and the clinical trials were classified in good, fair, or poor-quality
following the score algorithm proposed by the Agency for Healthcare Research and Quality [19].
If there was disagreement between the two evaluators, a third reviewer (RMLP) was required.
2.7. Categorization of Studies
Due to the fact that two types of studies, clinical trials, and case-control studies were analyzed in
this systematic review, the outcomes were grouped in two tables depending on the study design.
2.8. Synthesis of the Results
Given the great heterogeneity of the results, it could not be possible to perform a meta-analysis.
3. Results
3.1. Study Selection
The search strategy yielded 6201 studies (Figure 1). When the duplicates were removed,
2905 studies were left. Full title and abstract of each remaining article were screened individually.
Twenty-six full-text articles were assessed for eligibility. Of these, 13 were discarded (see reasons in
Figure 1). Finally, 13 publications were analyzed in full text.
3.2. Study Characteristics
Detailed information about the studies is shown in Table 1. Regarding the study design, five
publications were clinical trials and eight case-control studies. The largest sample was collected by De
la luz et al. [17] (n = 440) and the smallest by Nederfors et al. [20] (n = 12). Gender among these studies
was heterogeneous; there were also publications where gender was not available [21–23].
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Table 1. General characteristics of the studies.
Author, Year
and Country Study Design Duration Sample Age and Gender
Type of
Salivary Flow
Rate
Saliva Sampling Hyposalivation XerostomiaAssessment
Type of
Antihypertensive
Ben-Aryeh et
al., 1981, Israel
[29]
Clinical trial 6 weeks 10 CG10 HT
12 female/8 male
Mean age 54 years UWS
8–9 am
Spitting method
10 min
- - β-Adrenergicblocker (Pindolol)
Van Hoof et
al., 1983, The
Netherlands
[27]
Clinical trial 1 day 23 CG19 HT
42 Male
22–34 years UWS
15 min
cotton-wool method by.
Dollery et al.
- -
β-Adrenergic
blocker
(Propanolol)
α-Adrenergic
blocker
(Phentolamine)
Streckfus et al.,
1994, USA [24]
Case-control
study -
15 CG
20 HT
NT:
9 female/ 6 male
Mean age
69.5 years
HCTZ:
10 female/10 male
Mean age
68.5 years
SPS
8–12 am
Carlson–Crittenden cups:
parotid
- - Diuretic (HCTZ)
Nederfors et
al., 1995,
Sweden [28]
Double blind,
cross-over
randomized
trial
3 months
24 Healthy
patients:
Placebo
Captopril
13 female/ 11 male
Mean age 24 years
UWS
SWS
SPS
SSS
7.30–8.30 am
UWS: Spitting method
5 min
SWS: Spitting method
paraffin chewing 5min
SPS: Modified
Carlson–Crittenden cups
SSS: Nederfors modified
device 7.30–8.30 am
- - ACE inhibitors(Captopril)
Nederfors et
al., 2004,
Sweden [20]
Cross- over
clinical trial 3 months
12 Healthy
patients:
Placebo
Thiazide
Furosemide
12 female
Mean age 28 years
UWS
SWS
SPS
SSS
UWS: Spitting method
5 min
SWS: Spitting method
paraffin chewing 5min
SPS: Modified
Carlson–Crittenden cups
SSS: Nederfors modified
device
- VAS
Diuretic
(Thiazide,
furosemide)
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Author, Year
and Country Study Design Duration Sample Age and Gender
Type of
Salivary Flow
Rate
Saliva Sampling Hyposalivation XerostomiaAssessment
Type of
Antihypertensive
Tahrir et al.,
2006, Irak [30] Clinical trial 4 weeks
48 HT treated
with atenolol
48 CG
20 male /28 female
Mean age 49 years UWS
8–9 am
Spitting method
10 min
- - β-Adrenergicblockers: Atenolol
Nonzee et al.,
2012, Thailand
[25]
Case-control
study -
200 HT
200 CG
CG:
118 female/ 82 male
Mean age 58.82 ±
7.84 years
HT:
104 female/96 male
Mean age 62.41 ±
8.75 years
SWS
8–12 am
UWS: Modified Schirmer
test: 3 min
SWS: Spitting method
paraffin chewing 5min
Fontana et al.
Hyposalivation
SWS was
diagnosed if
the color of
Schirmer text
moved 25 mm
at 3 min
Xerostomia
questionnaire
Fox et al. +
VAS
β-Adrenergic
blockers
(Propanolol,
atenolol)
Diuretic (HCTZ)
ACE inhibitors
(Enalapril)
Calcium channel
blocker
(Amlodipine)
Muñoz et al.,
2012, Chile,
[21]
Case-control
study -
14 HT
10 CG
Gender not available
Age not available UWS
Not available
1 min - - Diuretics
De la luz et al.,
2013, Mexico
[17]
Case-control
study -
440 Patients:
CG
HT
268 female/ 172 male
Mean age 68.34 ±
6.19 years
UWS
SWS
Morning
UWS: Spitting method
3 min
SWS: Spitting method
Chewing no available
5 min
UWS < 0.15
mL/min
SWS < 0.5
mL/min
Modified
Sreebney and
Fox
questionnaire
Not available
Kagawa et al.,
2013, Japan
[26]
Case-control
study -
96 CG
9 Normotensive
treated with
antihypertensives
drugs
18 HT
92 female/73 male
Mean age 66.6 years
UWS
SWS
10 am-3 pm
UWS: Spitting method
5 min
SWS: Spitting method
paraffin chewing
2 min
- - Not available
Prasanthi et
al., 2014, India
[11]
Case-control
study -
50 CG
50 HT
CG
27 female/23 male
Mean age 43.9
±2.4 years
HT
23 female/27 male
Mean age 46.3
±2.7 years
UWS
SWS
9–10 am
UWS: Spitting method
5 min
SWS: Spitting method
paraffin chewing
5 min
UWS<0.3
mL/min
SWS<0.7
mL/min
- Diuretics
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Author, Year
and Country Study Design Duration Sample Age and Gender
Type of
Salivary Flow
Rate
Saliva Sampling Hyposalivation XerostomiaAssessment
Type of
Antihypertensive
Ivanovski et
al., 2015,
Republic of
Macedonia
[22]
Case-control
study -
30 CG
30 HT
Gender not available
30–70 years UWS
Navazesh method
10 min.
USW<0.2
mL/min -
Diuretic
β-Adrenergic
blockers
α-Adrenergic
blocker
ACE inhibitors
Calcium channel
blocker
Heart glycosides
Antihypertensives
drugs with central
effect
Nimma et al.
2016, India
[23]
Case-control
study -
20 CG
20 HT
Gender not available
60–75 years
UWS
SWS
Moment no available
UWS: Spitting method
5 min
SWS: Spitting method
paraffin chewing
5 min
- - Not available
UWS (unstimulated whole saliva), SWS (stimulated whole saliva), SPS (stimulated parotid saliva), USS (unstimulated submandibular/sublingual saliva), SSS (stimulated
submandibular/sublingual saliva), HT (hypertension treated with antihypertensives), GC (control group), DM (diabetes mellitus), HCTZ (hydrochlorothiazide), BD (blood pressure).
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Age of patients of the included studies was also heterogeneous. There were five studies that
included people ≥ 60 years old [17,23–26], three studies in where people included was younger than
34 years old [20,27,28], three studies in where the age was between 46 and 54 years old [11,29,30], and
one study in which the age ranged between 30 and 70 years old [22]. There was a publication where
age of patients was not available [21].
The xerostomia percentage was analyzed in two studies [17,25]. The xerostomia level was analyzed
only in three studies [17,20,25]. They used three different tools: VAS [20,25], xerostomia questions
proposed by Fox et al. [25] and other questionnaires like Xerostomia Inventory by Sreebney and Fox
modified by De la Luz et al. [17]. Hyposalivation was evaluated in four studies [11,17,22,25].
There were five studies in which UWS flow rate were collected [21,22,27,29,30], one study collected
SWS flow rate [25], one SPS flow rate [24], four UWS and SWS [11,17,23,26], and two studies collected
UWS, SWS, SPS, and SSS [20,28]. The UWS flow rate was the most collected, with 11 studies.
Different methods for saliva collection were used: the spitting method [11,17,20,23,25,26,28–30],
Carlson–Crittenden cups [20,24,28], Nederfors modified device [20,28], the cotton-wool method by
Dollery et al. [27], a modified Schirmer test [25], and the Navazesh method [22]. One study did not
show the method for saliva collection [21].
The schedule for saliva collection was before 12 a.m. in the majority of the studies, and five studies
did not show the schedule for saliva collection [21–23,27].
Clinical trials collected the saliva at different times. Two studies evaluated salivary flow at one day,
one week, and 4 weeks after treatment [29,30]. One study collected saliva 7 days after treatment [20].
One study evaluated the flow rate at 1 and 7 days after treatment [28]. Additionally, the last one
evaluated the flow rate after administering an antihypertensive intravenous injection [27].
The type of antihypertensives studied in the reviewed publications included β-adrenergic
blockers [22,25,27,29,30], diuretics [11,20–22,24,25], α-adrenergic blockers [22,27], calcium channel
blockers [22,25], and heart glycosides [22]. In three studies, the type of antihypertensives was not
available [17,23,26].
3.3. Risk of Bias within Studies
Regarding quality assessment, the clinical trials assessed presented many unclear biases, therefore
we considered that they were poor quality studies. As we reflected in Table 2, the major problems
were that the parameters included in the Cochrane risk assessment tool have not been described, so
according to the tool the suitable score for these cases was “unclear”.
On the other hand, quality assessment of five case-control studies obtained scores ranging from
4 to 5, so they were classified as poor quality [11,17,21,23,25]. Quality assessment of other three
case-control studies obtained scores of 6, so they were classified as fair quality [22,24,26]. The main
biases were present in the selection parameters (Table 3).
3.4. Main Findings
The results of the studies were divided in two groups depending on the type of study (clinical
trial (Table 4) or case-control (Table 5)).
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Table 2. The Cochrane risk of bias of the included clinical trials.
Random
Sequence
Generation
Allocation
Concealment
Blinding of
Participants
and Personnel
Blinding of
Outcome
Assessment
Incomplete
Outcome Data
Selective
Reporting
Other
Bias Quality
Ben-Aryeh 1981 High High High High Unclear Unclear Unclear Poor quality
Van Hoof et al. 1983 Unclear Unclear High Unclear Unclear Unclear Unclear Poor quality
Nederfors et al. 1995 Unclear Unclear Low Unclear Unclear Low Unclear Poor quality
Nederfors et al. 2004 Unclear Unclear Low Unclear Unclear Low Unclear Poor quality
Tahir et al. 2006 High High High High Unclear Unclear Unclear Poor quality
Table 3. The modified Newcastle–Ottawa scale for case-control studies.
Selection
(1)
Selection
(2)
Selection
(3)
Selection
(4)
Comparability
(1)
Outcome
(1)
Outcome
(2) Score Quality
Streckfus et al. 1994b [24] * - - * * ** * 6/10 Fair
Nonzee et al. 2012 [25] * - - - * ** * 5/10 Poor
Muñoz et al. 2012 [21] * - - - * * * 4/10 Poor
De la luz et al. 2013 [17] - - - - * ** * 4/10 Poor
Kagawa et al. 2013 [26] * - - * * ** * 6/10 Fair
Prasanthi et al. 2014 [11] * - - - * * * 4/10 Poor
Ivanovski et al 2015 [22] * - - * * ** * 6/10 Fair
Nimma et al. 2016 [23] - - - * * * * 4/10 Poor
* p < 0.001; ** p ≤ 0.05.
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Table 4. Clinical trials results.
Author/Year/Country Antihypertensive
Medications
Salivary Flow Rate (mL/min) (g/min)
Experimental No
Treatment
Placebo
Results
Before After Before After
Ben-Aryeh et al.,
1981, Israel [29]
β-Adrenergic
blocker (Pindolol) UWS: 0.24 ± 0.14
3 h 24 h 6 weeks UWS: 0.39
± 0.18
The UWS flow rate increased, no
significantly, in HT patients
treated with pinilol. However CG
salivary flow were higher than
experimental group.0.31 ± 0.11 0.27 ± 0.2 0.36 ± 0.15
Van Hoof et al. 1983
The Netherlands [27]
Intravenous
injection of
propranolol
1 mg 5 mg NT:
USW: 0.85
± 0.08 *
BHT:
USW: 0.51
± 0.04 *
UWS flow rate significantly
decreased in NT patients
treatment with propranolol and
phentolamine.
Salivary UWS flow rate was
significantly lower in BHT
patients no treatment than
normotensive patients.
NT: UWS: 0.88 ± 0.15 0.72 ± 0.12** 0.77 ± 0.12
BHT: UWS: 0.34 ± 0.04 0.32 ± 0.05 0.34 ± 0.04
Intravenous
injection of
phentolamine
1 mg 5 mg
NT: UWS: 0.88 ± 0.15 0.74 ± 0.14** 0.77 ± 0.11
BHT: UWS: 0.54 ± 0.14 0.47 ± 0.10 0.53 ± 0.10
Nederfors et al. 1995
Sweden [28]
ACE inhibitors
(Captopril)
UWS:0.59 ± 0.24
SWS:1.67 ± 0.57
SPS:1.41 ± 0.77
SSS:1.39 ± 0.51
Day 1 Day 7 -
UWS:
0.64 ± 0.57
SWS:
1.84 ± 0.60
SPS:
1.61 ± 0.82
SSS:
1.35 ± 0.63
Day 1 Day 7 SPS is significantly higher in
patients treated with captopril
UWS: 0.65 ± 0.27
SWS: 1.79 ± 0.47
SSP: 1.44 ± 0.84 **
SSS: 1.38 ± 0.71
UWS: 0.69 ±
0.69
SWS: 1.85 ±
0.46
SSP: 1.86 ±
0.91**
SSS: 1.41 ± 0.62
UWS:
0.65 ± 0.29
SWS:
1.95 ± 0.72
SPS:
1.62 ± 0.70
SSS:
1.57 ± 0.64
UWS:
0.62 ± 0.28
SWS:
1.81 ± 0.68
SPS:
1.56 ± 0.87
SSS:
1.57 ± 0.74
Nederfors et al. 2004
Sweden [20]
Diuretic (Thiazide,
furosemide)
Day 7 Day 7 SSS was significantly affected,
statistically (P < 0.05) decreased
in the morning during chronic
treatment with both drugs.
The percentage reduction in SSS
was 26 and 24% for
bendroflumethiazide and
furosemide, respectively.
Furosemide
UWS:
0.31 ± 0.12
SWS:
1.37 ± 0.54
SPS:
0.81 ± 0.44
SSS:
1.41 ± 0.57
Bendroflumethiazide
UWS:
0.34 ± 0.14
SWS:
1.34 ± 0.39
SPS:
0.76 ± 0.44
SSS:
1.27 ± 0.54
Furosemide
UWS:
0.29 ± 0.09
SWS:
1.34 ± 0.42
SPS:
0.83 ± 0.53
SSS:
1.05 ± 0.46**
Bendroflumethiazide
UWS:
0.30 ± 0.14
SWS:
1.29 ± 0.49
SPS:
0.76 ± 0.37
SSS:
0.96 ± 0.57**
UWS:
0.31 ± 0.12
SWS:
1.40 ± 0.39
SPS:
0.67 ± 0.12
SSS:
1.18 ± 0.56
UWS:
0.37 ± 0.20
SWS:
1.36 ± 0.37
SPS:
0.75 ± 0.42
SSS:
1.12 ± 0.49
Tahrir et al. 2006
Irak [30]
β-Adrenergic
blockers: Atenolol
UWS 0.24 ± 0.14 24 h 1 week 4 weeks UWS: 0.38± 0.18
The UWS flow rate increased, not
significantly, in HT patients
treated with atenolol0.26 ± 0.11 0.28 ± 0.2 0.33 ± 0.15
* p < 0.001; **p ≤ 0.05; UWS (unstimulated whole saliva), SWS (stimulated whole saliva), SPS (stimulated parotid saliva), USS (unstimulated submandibular/sublingual saliva), SSS
(stimulated submandibular/sublingual saliva), NT (normotensive), BHT (borderline hypertensive).
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Table 5. Case-control studies results.
Author/Year AntihypertensiveMedications UWS (mL/min) SWS (mL/min) SPS (mL/min)
Hyposalivation
Salivary Flow Rate
Hyposalivation
(%)
Xerostomia
(%)
Level of
Xerostomia
(cm)
p Value
Streckfus et
al., 1994b,
USA [24]
Diuretic (HCTZ) - -
CG: 0.695 ± 0.44
HT: 0.685 ± 0.39
HCTZ: 0.422 ±
0.24
Not available - - - 0.02
Nonzee et al.,
2012, Thailand
[25]
β-Adrenergic blockers
(Propanolol, atenolol)
Diuretic (HCTZ)
ACE inhibitor (Enalapril)
Calcium channel blocker
(Amlodipine)
- CG: 1.31 ± 0.34HT: 0.73 ± 0.30 -
SWS hyposalivation
was diagnosed if
the color moved
25 mm at 3 min
according to
Fontana et al.
CG: 5%
HT: 57%
CG: 25.5%
HT: 50%
CG: 1.53 ±
1.89
HT: 3.32 ±
2.72
0.05
Muñoz et al.,
2012, Chile
[21]
Diuretics CG: 1.92 ± 0.40HT: 0.57 ± 0.29 - - Not available - - - 0.13
De la luz et al.,
2013, Mexico
[17]
Not available CG: 0.31 ± 0.17HT: 0.27 ± 0.17
CG: 1.33 ± 0.70
HT: 1.12 ± 0.62 -
UWS < 0.15 mL/min
SWS < 0.5 mL/min -
CG: 12.7%
HT: 23.6%
UWS: 0.023
SWS: 0.001
Xerostomia
0.001
Kagawa et al.,
2013, Japan
[26]
Not available
CG: 0.32
(0.19–0.51) HT:
0.35 (0.23–0.57)
CG: 1.66
(1.18–2.39)
HT: 1.53
(1.01–2.07)
- Not available - - - UWS: 0.85SSS: 0.39
Prasanthi et
al., 2014 India
[11]
Diuretics CG: 2.16 ± 0.72HT: 0.88 ± 0.41
CG: 7.90 ± 1.87
HT: 2.71 ± 1.08 -
UWS < 0.3 mL/min
SWS < 0.7 mL/min - - - 0.001
Ivanovski et
al., 2015,
Republic of
Macedonia,
[22]
Diuretics
β-Adrenergic blockers
α-Adrenergic blocker
Angiotensin converting
enzyme inhibitors
Calcium channel blocker
Heart glycosides
Antihypertensives drugs with
central effect
CG: 0.6 ± 0.1
HT: 0.3 ± 0.2 - - USW < 0.2 mL/min - - - 0.000
Nimma et al.,
2016, India
[23]
Not available CG: 2.73 ± 0.68HT: 2.58 ± 0.37
CG: 3.30 ± 0.70
HT: 3.63 ± 0.65 - - - -
UWS: 0.13
SWS: 0.39
HT: hypertensive patients; CG: normotensive patients; METRO: metropolol; ENA: enalapril; HCTZ: hydrochlorothiazide.
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3.4.1. Clinical Trials (Table 4)
The study performed by Nederfors et al. 2004 using bendroflumethiazide as an antihypertensive
was the only study that analyzed the degree of xerostomia. They observed that patients treated with
thiazide or furosemide increased xerostomia levels [20].
The majority of the studies evaluated UWS flow rate. Three studies showed a non-significant
UWS increase after treatment with β-adrenergic blockers [29,30] or ACE inhibitors [28]. One study
obtained a statistically significant decrease in UWS in normotensives treated with propranolol and
phentolamine [27]. Additionally, the last study showed a no significant UWS decrease seven days after
treatment with diuretics [20].
With regard to the SWS, there were only two studies. One of them presented a non-significant
decrease in hypertensive patients treated with furosemide or bendroflumathiazide [20]. The other one
obtained a non-significant increase after treatment with captopril [28].
Of the two studies that analyzed SPS flow rate, one obtained an SPS flow rate statistically elevated
after treatment with captopril [28]. The other one did not obtain significant changes after treatment
with bendroflumethiazide [20].
For the SSS the results were also heterogeneous, showing one study that did not have significant
changes in patients treated with captopril [28] and the other one had a significant decrease after
treatment with furosemide and bendroflumethiazide [20].
3.4.2. Case-Control Studies (Table 5)
Xerostomia was studied in two articles [17,25]. In one of them [25] the percentage and degree
of xerostomia were collected in patients treated with ACE inhibitors, calcium channel blockers,
β-adrenergic blockers, and diuretics obtaining a statistically significant higher percentage and level of
xerostomia in the hypertensive group. The other study only showed that the percentage of xerostomia
was significantly greater in patients receiving antihypertensives, but it did not describe the drugs
used [17].
Nonzee et al. 2012 was the only study that presented the percentage of patients with hyposalivation,
being significantly greater in hypertensive patients treated with ACE inhibitors, calcium channel
blockers, β-adrenergic blockers, and diuretics [25].
Six studies analyzed the UWS flow rate [11,17,21–23,26] and in all of them patients receiving
antihypertensives had a lower salivary flow than CG, acquiring statistical significance in three of
them [11,17,22].
Five publications studied SWS flow rate [11,17,23,25,26]. In four of them SWS [11,17,25,26] flow
rate was lower in patients receiving antihypertensives, acquiring statistical signification in three of
them [11,17,25].
SPS was recorded in one study and the hypertensive patients were treated with diuretics [24].
SPS flow rate was significantly lower in patients treated with hydrochlorothiazide.
4. Discussion
This systematic review showed the available evidence about a possible relationship between
taking antihypertensives and xerostomia, hyposalivation, and a decrease in the salivary flow rate.
Xerostomia and hyposalivation can have a detrimental effect on a patient’s quality of life leading to
situations such as stress or anxiety [9]. Furthermore, a salivary flow decrease can increase susceptibility
to dental caries or oral fungal infections, so these conditions must be given the importance they
deserve [7].
The results of this study show that the possible relationship between antihypertensive intake
and salivary alterations is not clear. The studies that deal with this topic were not abundant and in
addition the existing ones did not have a high methodological quality. Besides, the available clinical
trials about this topic were not current. The most recent was from 2006 [30] and the oldest one from
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1981 [29]. In general terms, study design was heterogeneous from sample size, antihypertensive drugs
used, duration of the study, type of salivary flow collection, or the saliva sampling method. Clinical
trials included in this study had a small sample and the sample size was not calculated in any of them.
In the case–control studies, the samples are higher in number, but the majority of the studies did not
give a detailed explanation of the method used to obtain the sample.
According to the studies that evaluated hyposalivation [11,17,22,25], the UWS and SWS cut-off
values are heterogeneous, and the majority not those currently used. Therefore, we believe that further
investigation would be necessary about this topic.
Only three studies [17,20,25], included in this systematic review, assessed xerostomia. Currently,
there are different xerostomia assessment questionnaires but the only one validated to measure
xerostomia level in patients receiving drugs is the Xerostomia Inventory [31] and is probably the best
for researching on medication-induced salivary gland disorders [9]. In this systematic review, none
of the studies used this test to assess the level of xerostomia. However, De la Luz et al. [17] used a
modified Xerostomia Inventory different from the one validated by Thomson et al.
The types of saliva collected were different between the studies. Individual gland secretions are
superior to whole saliva for many compositional analyses, because whole saliva contains non-salivary
elements such as desquamated epithelial cells, food debris, bacteria, gingival crevicular fluid, and
leukocytes. However, for the assessment of overall salivary gland dysfunction, whole saliva (UWS and
SWS) is superior and clinically more relevant [32]. Furthermore, Navazesh stated in their study the
methods for collecting saliva were that patients avoid smoking, eating or drinking 1–2 h before the
appointment, and to remember that salivary flow rate is affected by a seasonal and diurnal factor [9,32].
For this reason, it is important to standardize the time of the day for saliva collection, and should
be considered in long-term salivary studies about this topic. The schedule for saliva collection was
before 12 am in the majority of the studies, except in five studies that did not show the time for saliva
collection [21–23,27].
According to clinical trials, xerostomia was only studied in the Nederfors et al. study [20]. The
level of xerostomia in the placebo group maintained a similar level while the two antihypertensive
groups (patients treated with thiazide or furosemide) increased the xerostomia level. Hyposalivation
was not studied in any. All the studies measured UWS flow rate; however only one showed a
statistically significant UWS flow rate decreased in patients treated with an α-Adrenergic blocker and
β-Adrenergic blocker [27]. Two studies measured SWS, SPS, and SSS flow rate [20,28]. One study
showed a significant increase in SPS flow rate in patients treated with ACE inhibitors [28]. Additionally,
the last one showed a significant SSS flow rate decrease in patients treated with diuretics [20].
For the case-control studies, the results are more logical regarding the current knowledge.
Hyposalivation was studied in one manuscript, and it showed a greater number among patients taking
antihypertensives than in CG [25]. Two articles studied xerostomia [17,25], and it was also higher in
hypertensive patients than CG. Six studies measured UWS flow rate. Five of them showed a UWS
decrease [11,17,21–23] acquiring statistical significance in three studies [11,17,22]. However, one of the
studies showed a UWS flow increase [26]. Five studies measured the SWS flow rate. Three of them
showed a significant SWS decrease [11,17,25]. One study measured SPS [24] obtaining a significant
decrease in patients treated with diuretics.
The type of antihypertensives studied in case-control studies included β-adrenergic blockers,
α-adrenergic blockers, diuretics, ACE inhibitors, calcium channel blockers, heart glycosides, and
antihypertensive drugs with central effects. Due to the great heterogeneity of the study designs, and
the different outcomes it was impossible to ensure if one antihypertensive produces more xerostomic
effects than other.
Our review, thus far, had some limitations. Studies published in languages other than English
and Spanish were not included. We also excluded the studies if the salivary flow rate was not shown
in numerical data but in a graph or a box-plot without exact data. Another limitation is that we
have also not been able to evaluate whether the duration of treatment influences the appearance
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of salivary disorders because case–control studies did not offer the time these patients had been on
antihypertensive treatment. Finally, we did not include studies whose patients had concomitant
diseases or took other drugs that can alter salivary flow. So, we could not evaluate if antihypertensives
used in combination with other drugs could increase salivary disorders.
5. Conclusions
The available literature about this topic is scarce and based on the quality assessment performed
we believe that there is a need for future research on this subject. Correct methodological studies with
an adequate sample calculation to provide strong evidence should be performed. Long-term clinical
trials are also needed to analyze if the effects of xerostomia/hyposalivation emerge after larger periods
of time. It could be interesting to carry out long-term randomized clinical trials in which different
antihypertensives at standardized doses were tested against a placebo/CG to elucidate which drug
further reduces salivary flow. Future studies could help to understand which antihypertensive is more
suitable for patients in terms of oral dryness, always within the limits of the drug´s indication.
Trying to respond to our focused questions we could say that: (1) With the current literature it was
not possible to assure that patients taking antihypertensives have more xerostomia or hyposalivation
than patients not taking antihypertensives. (2) With respect to the salivary flow rate, only two clinical
trials found a statistically significant decrease in the flow rate after antihypertensive treatment, and
one clinical trial showed a statistically significant increase in flow rate after antihypertensive treatment.
So, we could not say that antihypertensives reduced salivary flow. The possible decrease could not be
confirmed by case–control studies due to the great variability of saliva collection, but most studies
found less salivary flow in the antihypertensive treatment group than in CG. (3) Finally, the type of
antihypertensives studied in the reviewed publications included β-adrenergic blockers, α-adrenergic
blockers, diuretics, ACE inhibitors, calcium channel blockers, heart glycosides, and antihypertensive
drugs with central effects. Due to the great heterogeneity of the types of antihypertensives, the study
design and the different outcomes made it impossible to ensure if one antihypertensive produced
more xerostomic effect than other. Due to these results, future studies about this topic are necessary to
confirm if antihypertensive drugs produce salivary alterations.
Author Contributions: Conceptualization: L.R.M.-A., F.H.R.d.A. and R.M.L.-P.; Data collection and extraction:
L.R.M.-A., F.H.R.d.A. and R.M.L.-P.; Risk of bias evaluation: L.R.M.-A., F.H.R.d.A. and R.M.L.-P.; Writing—original
draft: L.R.M.-A., F.H.R.d.A. and R.M.L.-P.; Writing—review and editing: J.S., E.C. and G.H. All authors have read
and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redón, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.;
De Backer, G.; Dominiczak, A.; et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension,
the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC). J. Hypertens. 2013, 31, 1281–1357. [CrossRef] [PubMed]
2. Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E.; Collins, K.J.; Dennison Himmelfarb, C.;
De Palma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/
APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation and management of
high blood pressure in adults, executive summary, a report of the American college of cardiology/American
Heart Association task force on clinical practice guidelines. Hypertension 2018, 71, 1269–1324.
3. Williams, B.; Mancia, G.; Spiering, W.; Rosei, E.A.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.;
De Simone, G.; Dominiczak, A.; et al. Guidelines for the management of arterial hypertension. Eur. Heart J.
2018, 39, 3021–3104. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2020, 17, 2478 15 of 16
4. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015, a pooled analysis
of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017, 389, 37–55.
[CrossRef]
5. De Palma, S.M.; Himmelfarb, C.D.; MacLaughlin, E.J.; Taler, S.J. Hypertension guideline update: A new
guideline for a new era. J. Am. Acad. Phys. 2018, 31, 16–22.
6. Niklander, S.; Veas, L.; Barrera, C.; Fuentes, F.; Chiappini, G.; Marshall, M. Risk factors, hyposalivation and
impact of xerostomia on oral health-related quality of life. Braz. Oral Res. 2017, 31, e14. [CrossRef]
7. Carramolino-Cuéllar, E.; Lauritano, D.; Silvestre, F.J.; Carinci, F.; Lucchese, A.; Silvestre-Rangil, J. Salivary
flow and xerostomia in patients with type 2 diabetes. J. Oral Pathol. Med. 2018, 47, 526–530. [CrossRef]
8. Proctor, G.B. The physiology of salivary secretion. Periodontology 2016, 70, 11–25. [CrossRef]
9. Villa, A.; Connell, C.L.; Abati, S. Diagnosis and management of xerostomia and hyposalivation.
Clin. Risk Manag. 2014, 11, 45–51. [CrossRef]
10. Aliko, A.; Wolff, A.; Dawes, C.; Aframian, D.; Proctor, G.; Ekström, J.; Narayana, N.; Villa, A.; Sia, Y.W.;
Joshi, R.K.; et al. World Workshop on Oral Medicine VI, clinical implications of medication-induced salivary
gland dysfunction. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2015, 120, 185–206. [CrossRef]
11. Prasanthi, B.; Kannan, N.; Patil, R. Effect of diuretics on salivary flow.; composition and oral health status,
A clinico-biochemical study. Ann. Med. Health Sci. Res. 2014, 4, 549–553. [CrossRef] [PubMed]
12. Saleh, J.; Figueiredo, M.A.Z.; Cherubini, K.; Salum, F.G. Salivary hypofunction: An update on aetiology,
diagnosis and therapeutics. Arch. Oral Biol. 2015, 60, 242–255. [CrossRef] [PubMed]
13. Djukic´, L.; Roganovic´, J.; Brajovic´, M.; Bokonjic´, D.; Stojic´, D. The effects of anti-hypertensives and type 2
diabetes on salivary flow and total antioxidant capacity. Oral Dis. 2015, 21, 619–625. [CrossRef]
14. Higgins, J.; Altman, D.; Gøtzsche, P.; Jüni, P.; Moher, D.; Oxman, A.; Savovic´, J.; Schulz, K.F.; Weeks, L.
The Cochrane´s collaboration tool for assessing risk of bias in randomized trials. BMJ 2011, 343, d5928.
[CrossRef] [PubMed]
15. Scott, J.; Huskisson, E.C. Graphic representation of pain. J. Pain 1976, 2, 175–184. [CrossRef]
16. Fox, P.C.; Busch, K.A.; Baum, B.J. Subjective reports of xerostomia and objective measures of salivary gland
performance. J. Am. Dent. Assoc. 1987, 115, 581–584. [CrossRef]
17. De la luz, M.; Barrios, B. Salivary flow and the prevalence of xerostomia in geriatric patients. Rev. Asoc.
Dent. Mex. 2013, 70, 25–29.
18. Modesti, P.A.; Reboldi, G.; Cappuccio, F.P.; Agyemang, C.; Remuzzi, G.; Rapi, S.; Perruolo, E.; Parati, G.
Panethnic differences in blood pressure in Europe, a systematic review and meta-analysis. PLoS ONE 2016,
11, e0147601. [CrossRef]
19. McPheeters, M.L.; Kripalani, S.; Peterson, N.B.; Idowu, R.T.; Jerome, R.N.; Potter, S.A.; Andrews, J.S. Closing
the quality gap, revisiting the state of the science (vol. 3, quality improvement interventions to address
health disparities). Evid. Rep. Technol. Assess. 2012, 208, 1–475.
20. Nederfors, T.; Nauntofte, B.; Twetman, S. Effects of furosemide and bendroflumethiazide on saliva flow rate
and composition. Arch. Oral Biol. 2004, 49, 507–513. [CrossRef]
21. Muñoz, L.S.; Narváez, C.G. Salivary pH, buffer capacity, total proteins and salivary flow in controlled
hypertensive patients diuretic users. Int. J. Odontostomat. 2012, 6, 11–17. [CrossRef]
22. Ivanovski, K.; Pesevka, S.; Ristoska, S.; Dirjanska, K.; mindova, S.; Pandilova, M.; Georgieva, S.; Stefanovska, E.;
Filipce, V.; Apostolska, S.; et al. The impact of antihypertensive medications on quantitative and qualitative
characteristics of saliva. J. Pharm. Biol. Chem. Sci. 2015, 6, 1356–1364.
23. Nimma, V.; Talla, H.; Poosa, M.; Gopaladas, M.; Meesala, D.; Jayanth, L. Influence of hypertension on pH
of saliva and flow rate in elder adults correlating with oral health status. J. Clin. Diagn. Res. 2016, 10,
ZC34–ZC36. [CrossRef] [PubMed]
24. Streckfus, C.F.; Wu, A.J.; Ship, J.A.; Brown, L.J. Stimulated parotid salivary flow rates in normotensive,
hypertensive, and hydrochlorothiazide-medicated African-Americans. J. Oral Pathol. Med. 1994, 23, 280–283.
[CrossRef]
25. Nonzee, V.; Manopatanakul, S.; Khovidhunkit, S.; Xerostomia, O. Hyposalivation and oral microbiota in
patients using antihypertensive medications. J. Med. Assoc. Thail. 2012, 95, 96–104.
26. Kagawa, R.; Ikebe, K.; Enoki, K.; Murai, S.; Okada, T.; Matsuda, K.; Maeda, Y. Influence of hypertension on
pH of saliva in older adults. Oral Dis. 2013, 19, 525–529. [CrossRef]
Int. J. Environ. Res. Public Health 2020, 17, 2478 16 of 16
27. Van Hooff, M.; Van Baak, M.A.; Schols, M.; Rahn, K.H. Studies of salivary flow in borderline hypertension,
effects of drugs acting on structures innervated by the autonomic nervous system. Clin. Sci. 1984, 66, 599–604.
[CrossRef]
28. Nederfors, T.; Dahlöf, C.; Ericsson, T.; Twetman, S. Effects of the antihypertensive drug captopril on human
salivary secretion rate and composition. Eur. J. Oral Sci. 1995, 103, 351–354. [CrossRef]
29. Ben-Aryeh, H.; Schiller, M.; Shasha, S.; Szargel, R.; Gutman, D. Salivary composition in patients with essential
hypertension and the effect of pindolol. J. Oral Med. 1981, 36, 76–78.
30. Tahrir, N.N.; Aldelaimi, B.D.S. The effect of atenolol (B- blocker) on salivary composition in patients with
essential hypertension. J. Baghdad. Coll. Dent. 2006, 18, 57–59.
31. Thomson, W.M.; Chalmer, J.M.; Spencer, A.J.; Willians, S.M. The Xerostomia Inventory: A multi-item
approach to measuring dry mouth. Community Dent. Health 1999, 16, 12–17. [PubMed]
32. Navazesh, M. Methods for collecting saliva. Ann. N. Y. Acad. Sci. 1993, 20, 694–727. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
